Tevogen Bio Entered Into A Binding Term Sheet With An Existing Investor To Secure Up To $50M Of Financing
Tevogen Bio Entered Into A Binding Term Sheet With An Existing Investor To Secure Up To $50M Of Financing
-
Supports expansion of Tevogen's ExacTcell platform toward additional clinical trials
- Bolsters a financial path to positive cashflow and minimizes dilution
- 支持將 Tevogen 的 ExactCell 平台擴展到更多臨床試驗
- 爲通往正現金流的財務路徑提供支持，並最大限度地減少稀釋
WARREN, N.J., May 10, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or "Tevogen Bio") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, has entered into a binding term sheet [with an existing investor] to secure up to $50 million of financing.
新澤西州沃倫，2024年5月10日（GLOBE NEWSWIRE）——臨床階段的特種免疫療法生物技術先驅Tevogen Bio Holdings Inc.（“Tevogen” 或 “Tevogen Bio”）（納斯達克股票代碼：TVGN）是開發腫瘤、神經病學和病毒學現成的、未經轉基因的T細胞療法的先驅，已與現有投資者簽訂了具有約束力的條款表高達5000萬美元的融資。
This financing supports Tevogen Bio's pursuit of expanding research and development efforts with a focus on continued clinical development of the company's initial product, TVGN 489, from its ExacTcell technology platform. In January 2023, Tevogen Bio announced positive proof-of-concept clinical trial results of TVGN 489 for treatment of high-risk patients. The financing will also be utilized to facilitate Tevogen Bio's efforts to start additional clinical trials for virally induced cancers and multiple sclerosis.
這筆融資支持Tevogen Bio尋求擴大研發工作，重點是通過其ExactCell技術平台繼續對公司的初始產品TVGN 489進行臨床開發。2023年1月，Tevogen Bio宣佈了用於治療高危患者的TVGN 489的概念驗證臨床試驗陽性結果。這筆資金還將用於促進Tevogen Bio啓動更多針對病毒誘發的癌症和多發性硬化症的臨床試驗。
譯文內容由第三人軟體翻譯。